INTRAOCULAR BIOACTIVE AGENT DELIVERY SYSTEM WITH MOLECULAR PARTITIONING SYSTEM

• US 20100278897A1
• Filed: 05/01/2009
• Published: 11/04/2010
• Est. Priority Date: 05/01/2009
• Status: Abandoned Application

• Current Assignee: Allergan Incorporated (Abbvie Incorporated)
• Original Assignee: Allergan Incorporated (Abbvie Incorporated)
• Inventors: SHI, Ruiwen, Hughes, Patrick M.
• Application Number:
  US12/434,541
• Publication Number:
  US 20100278897A1
• Time in Patent Office: Days
• US Class Current: 424/427
• CPC Class Codes: A61K 31/496 Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• CPC Class Codes: A61K 9/0051 Ocular inserts, ocular implants
• CPC Class Codes: A61P 27/02 Ophthalmic agents

Abstract

The present disclosure generally provides intraocular implants including at least one therapeutic bioactive agent and a molecular partitioning system. The molecular partitioning system comprises at least two phases wherein the first phase has an inherent viscosity equal or greater than the inherent viscosity of a second phase. The molecular partitioning system allows the intraocular implants to controllably release the at least one therapeutic bioactive agent into the surrounding tissues once implanted.

Claims

1. An intraocular implant for treating an ocular condition, the implant comprising:

a molecular partitioning system comprising a poly(D,L-lactide) phase having a first inherent viscosity;

a poly(D,L-lactide-co-glycolide) phase having a second inherent viscosity; and

at least one therapeutic bioactive agent;

wherein said first mean viscosity is at least about four times greater than said second mean viscosity, and wherein said molecular partitioning system provides controlled release of said at least one therapeutic bioactive agent from said intraocular implant.

2. The intraocular implant according to claim 1 wherein said poly(D,L-lactide) phase has a first molecular weight and said poly(D,L-lactide-co-glycolide) phase has a second molecular weight wherein said first molecular weight is at least four times greater than said second molecular weight.

3. The intraocular implant according to claim 1 wherein said poly(D,L-lactide) phase, said poly(D,L-lactide-co-glycolide) phase, and said at least one therapeutic bioactive agent are present at a ratio of about 60:

20;

20.

4. The intraocular implant according to claim 1 wherein said at least one therapeutic bioactive agent is a tyrosine kinase inhibitor having the structure

5. The intraocular implant according to claim 1 wherein said at least one therapeutic bioactive agent is greater than about 60% partitioned into said poly(D,L-lactide-co-glycolide) phase.

6. The intraocular implant according to claim 1 wherein said at least one therapeutic bioactive agent is greater than about 75% partitioned into said poly(D,L-lactide-co-glycolide) phase.

7. A process for making an intraocular implant having a molecular partition system comprising:

dissolving a poly(D,L-lactide) polymer having a first mean viscosity;

a poly(D,L-lactide-co-glycolide) polymer having a second mean viscosity; and

at least one therapeutic bioactive agent in a solvent thereby forming a mixture;

casting said mixture;

evaporating said solvent thereby forming a polymeric film comprising said molecular partitioning system, said molecular partitioning system comprising a poly(D,L-lactide) phase having said first mean viscosity and a poly(D,L-lactide-co-glycolide) phase having said second mean viscosity; and

extruding said polymer film thereby making said intraocular implant,

wherein said first mean viscosity is at least about four times greater than said second mean viscosity and said molecular partitioning system provides controlled release of said at least one therapeutic bioactive agent from said intraocular implant.

8. The method according to claim 7 wherein said poly(D,L-lactide) polymer, said poly(D,L-lactide-co-glycolide) polymer, and said at least one therapeutic bioactive agent are present at a ratio of about 60:

20;

20.

9. The method according to claim 7 wherein said at least one therapeutic bioactive agent is a tyrosine kinase inhibitor having the structure

10. The method according to claim 7 wherein said at least one therapeutic bioactive agent is greater than about 60% partitioned into said poly(D,L-lactide-co-glycolide) phase.

11. The method according to claim 7 wherein said at least one therapeutic bioactive agent is greater than about 75% partitioned into said poly(D,L-lactide-co-glycolide) phase.

12. The method according to claim 7 wherein said extruding step is performed at a temperature of about 90°

C.

13. A method of treating an ocular condition comprising the steps of:

(a) selecting a patient with an ocular condition in need of treatment;

(b) providing an intraocular implant comprising a molecular partitioning system comprising a poly(D,L-lactide) phase having a first mean viscosity;

a poly(D,L-lactide-co-glycolide) phase having a second mean viscosity; and

at least one therapeutic bioactive agent, wherein said first mean viscosity is at least about four times greater than said second mean viscosity, and wherein said molecular partitioning system provides controlled release of said at least one therapeutic bioactive agent from said intraocular implant;

(c) inserting said intraocular implant into a region of an eye; and

(d) treating said ocular condition.

14. The method of treating an ocular condition according to claim 13 wherein said poly(D,L-lactide) phase, said poly(D,L-lactide-co-glycolide) phase, and said at least one therapeutic bioactive agent are present at a ratio of about 60:

20;

20.

15. The method of treating an ocular condition according to claim 13 wherein said at least one therapeutic bioactive agent is a tyrosine kinase inhibitor having the structure

16. The method of treating an ocular condition according to claim 13 wherein said at least one therapeutic bioactive agent is greater than about 60% partitioned into said poly(D,L-lactide-co-glycolide) phase.

17. The method of treating an ocular condition according to claim 13 wherein said at least one therapeutic bioactive agent is greater than about 75% partitioned into said poly(D,L-lactide-co-glycolide) phase.

18. The method of treating an ocular condition according to claim 13 wherein said ocular implant is rod shaped.

19. A process of making an intraocular implant having a molecular partitioning system comprising:

dissolving a poly(D,L-lactide) polymer having a mean viscosity between about 1.3 and about 1.7 dl/g ;

a poly(D,L-lactide-co-glycolide) polymer having a mean viscosity between about 0.32 and about 0.44 dl/g; and

at least one bioactive agent in dichloromethane thereby forming a mixture;

casting said mixture;

evaporating said dichloromethane thereby forming a polymer film comprising said molecular partitioning system having a poly(D,L-lactide) phase and a poly(D,L-lactide-co-glycolide) phase; and

extruding said polymeric film into rod shaped structures at a temperature of about 90°

C. thereby making said intraocular implant,

wherein said molecular partitioning system provides controlled release of said at least one bioactive agent from said intraocular implant.

20. The method of making an intraocular implant according to claim 19 wherein said poly(D,L-lactide) polymer, said poly(D,L-lactide-co-glycolide) polymer, and said at least one bioactive agent are present at a ratio of about 60:

20;

20.